Biopharmaceutical Manufacturing, Upstream, Downstream …
Biopharmaceutical Manufacturing, Upstream, Downstream processing news. News and analysis on the clinical development and manufacture of large molecule drugs. Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases. The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager.
Cytiva and Pall Life Sciences complete integration: ‘Uniting gives …
May 2, 2023 · Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells us how the company will focus its efforts moving forward to support long-term growth of the biotech industry.
GE Healthcare Life Sciences becomes Cytiva
Apr 1, 2020 · GE Healthcare Life Sciences completes transition into Cytiva. As Danaher’s $21bn acquisition completes, GE Life Sciences rebrands to ‘Cytiva’ and, with the COVID-19 pandemic, its CEO tells us demand is high. In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation ...
AstraZeneca invests $135M on expanding biologics facility in …
Aug 29, 2024 · AstraZeneca has announced plans to expand its existing manufacturing operations at the Sweden Biomanufacturing Center in Södertälje, a Swedish town located near Stockholm. The company will spend $135 million in the expansion, making it the largest single investment in the facility since it was inaugurated back in 2021.
Jade Biosciences raises $80M for autoimmune disease therapies
Aug 6, 2024 · News and analysis on the clinical development and manufacture of large molecule drugs. Jade Biosciences raises $80M to develop targeted therapies for autoimmune diseases. The fundraising will support the development of best-in-class biologics for indications across inflammation and immunology with high unmet needs.
New wave of potential therapies to bring ‘paradigm shift’ in COPD …
Mar 25, 2024 · According to data and analytics firm GlobalData, this new wave of potential therapies will bring a shift in the treatment paradigm for COPD. The company predicts total sales for Dupixent to reach $21.4 billion globally by 2029, and ensifentrine is forecast to record sales of $1.1 billion by 2029. Asiyah Nawab, pharma analyst at GlobalData, said ...
Novo Nordisk and Catalent deal: net positive or negative for …
Feb 20, 2024 · The deal is part of a wider agreement in which Novo Holdings, the controlling shareholder of Novo Nordisk, will purchase Catalent for $16.5 billion. The tie-up also signals Novo's strategy to keep up with surging demand for its diabetes and obesity drugs Ozempic and Wegovy, whose huge popularity has increased the company’s valuation beyond ...
BioNTech starts Phase 1 trial for herpes virus vaccine
Dec 21, 2022 · BioNTech has dosed the first participant in a Phase 1 trial for BNT163, a herpes simplex virus (HSV) vaccine candidate for HSV-2 and potentially HSV-1. The trial will evaluate the safety, tolerability and immunogenicity of the prophylactic mRNA candidate in preventing genital lesions caused by the viruses. Herpes Simplex Virus-1 (HSV-1) and ...
Kyverna Therapeutics’ CAR-T cell therapy shows promise against ...
Jun 10, 2024 · Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases. In a landmark study involving 50 patients, KYV-101, an autologous, fully human anti-CD19 CAR-T cell therapy, has demonstrated broad efficacy across a diverse range of autoimmune conditions.
Resolution Therapeutics secures $83M to advance liver therapy
Oct 3, 2024 · Resolution Therapeutics was co-founded by Syncona, a UK-based investment trust focused on helping to found, fund and progress healthcare companies, in 2020 after a two-year collaboration with scientific co-founders Stuart Forbes, a professor at the University of Edinburgh and his team, and John Campbell, Director of Tissues, Cells and Advanced Therapeutics at the Scottish National Blood ...